ArticleOdontology2026
Evaluation of angiogenic, osteogenic, and antimicrobial potential of novel type X collagen-derived GBR membrane: an in vivo preliminary study.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of infection with traditional GBR membranes is a drawback that increases the risk of bone transplant failure. Using an in vivo preclinical model, this unique type X collagen-derived GBR membrane produced from chicken eggs demonstrated angiogenic, osteogenic, and antimicrobial potentials. The aim of the study was to assess the angiogenic, osteogenic, and antibacterial properties of a unique type X collagen-derived GBR membrane. Gelatin, zinc nanoparticles, and eggshell membranes were used to create GBR membranes produced from type X collagen. Each experiment was performed three times to ensure accuracy and precision in characterizing the unique GBR membrane using SEM and EDX analysis. MTT assay was used to examine the osteogenic properties of MG63 cells. Antimicrobial activity against Propionibacterium gingivalis was ascertained using the Kirby-Bauer test. Angiogenic properties were evaluated using the chorioallantoic membrane (CAM) test. Data are presented as mean ± standard deviation. One-way analysis of variance (ANOVA) was conducted for cases in which P < 0.05. The GBR membrane, made from type X collagen, exhibited sufficient tensile strength. The presence of zinc, with a mass percentage of 22.14 ± 0.46, was confirmed by EDX examination. When tested against P. gingivalis, a broad zone of inhibition was observed. The MTT assay demonstrated the presence of a novel type X collagen-derived GBR membrane (2.57 OD) that showed definite changes in the proliferation of MG 63 cells. After 8 days of incubation, histological staining showed that the incubated CAM had a strong angiogenic ability, with numerous allantoic capillaries developing and radiating toward the novel GBR membrane. The biosynthesized novel GBR membrane showed high angiogenic, osteogenic, and bactericidal properties, which were statistically significant (P < 0.005). The novel GBR membrane showed angiogenic, osteogenic, and antimicrobial potentials.
Indexed as
Identifiers
40783478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.